Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.8 USD | +1.58% | +1.73% | -37.43% |
Apr. 25 | Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained | MT |
Apr. 25 | Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.43% | 817M | |
-2.51% | 103B | |
+0.27% | 95.71B | |
+2.04% | 22.02B | |
-16.81% | 20.9B | |
-9.03% | 17.85B | |
-42.83% | 16.21B | |
-14.96% | 15.52B | |
+3.15% | 13.86B | |
+34.85% | 12.04B |
- Stock Market
- Equities
- SAGE Stock
- News Sage Therapeutics, Inc.
- Citigroup Trims Price Target on Sage Therapeutics to $40 From $41, Maintains Neutral Rating